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018: Single-cell genotyping and targeted genome
sequencing techniques
Mats Nilsson
Uppsala University, Department of Genetics and Pathology, Rudbeck
Laboratory, Se-751 85 Uppsala, Sweden
Most genetic studies of multi-factorial disease generate a large set of
loci associated with disease phenotypes. To identify the exact
molecular alteration behind the association, full sequence information
from these loci is often required from a large number of affected and
control subjects. Even with current development in sequencing
capacity, it will remain too expensive to sequence whole genomes.
We have developed a technique to efficiently extract relevant parts of
genomes for sequencing. We have further developed a rapid, simple,
and cost-effective assay to detect copy-number variation, which is a
common cause of multi-factorial disease. Mutations often cause
aberrant expression in specific cells. Ultimately, expression levels
should be measured on a single-cell level, and preferably in the
preserved context of tissues, not to overlook alterations in minority
cell populations. We are developing an in situ genotyping technique
that allows detection of individual transcript molecules with allelic
resolution in tissue samples.
019: Design and implementation of a high-throughput,
high content RNAi screen for endocytosis
in metazoan cells
Satyajit Mayor
National Centre for Biological Sciences, Bangalore, India
It is increasingly evident that endocytosis in metazoan cells occurs
through multiple specialized yet interconnected pathways. For many
of these though, in particular clathrin independent (CI) modes of
endocytosis, little is known about their regulatory circuits and
molecular machinery. We have used the adherent Drosophila
SR + cell line and a custom designed high-throughput, high content
fluorescence microscopy to screen endocytic phenotypes using RNAi
to 7,216 genes, chosen for their conservation between human and
flies. We have simultaneously monitored two endocytic pathways,
the canonical clathrin mode marked by endocytosis of transferrin and
the CI-GEEC pathway marked by fluorescent dextran. Cells were
grown and assayed on a customized glass slide followed by semi-
automated image acquisition. Custom-written MATLAB routines
were used to identify single cells and extract quantitative measures
of endocytic uptake. The design of this screen provides quantitative
data at both the single cell and population level. Heterogeneous
responses to RNAi within a single population of cells allowed us to
develop novel statistical indicators of perturbation. These indicators
are robust to the systematic noise characteristic of such large-scale
experiments. Candidate genes from the primary screen are being
channelled through independent confirmatory experiments which
have served to validate both the set of ‘hits’ and the statistical
methodology, and provide a comprehensive genetic landscape for the
understanding of this fundamental cellular process. The analysis of
quantitative phenotypic data from cells and their populations in
large-scale screens may be generally useful for exploring biological
networks.
020: Technologies for personal genomics: exomes,
allele-specific-RNAs, microbiomes, VDJomes
George Church
Harvard Medical School, 77 Ave Louis Pasteur, USA
Relative to the 2004 reference human genome, a personal genome
shows about 10,000 DNA variations which affect protein structure and
three million which do not. While association studies of common alleles
with diseases mostly yield, so far, weak predictive power and few
causative alleles. Most researchers expect that this will be soon reme-
died by genome-wide sequencing and aggregating alleles by system
functions. Second-generation sequencing (e.g. http://www.Polonator.
org/–uniquely open-source for hardware, software, wetware) has
brought costs down by 10,000-fold (from $300 M to $30 K), but to get
to a true mass market requires a cost less than $1,000—which for now
requires targeted sequencing including coding variants (*1% of the
genome), regulatory variants (RNA quantitation by sequencing), mi-
crobiome and VDJ-ome). We use solution hybridization capture
for [10 kbp contiguous regions, but for more precision (e.g. 100 bp
exons) we can cut cost by 10-fold by using circle-capture methods.
http://www.PersonalGenomes.org/is a unique effort to integrate these
with comprehensive sets of medical and non-medical traits and envi-
ronmental measures and provide these in an open-access format. To
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gain access to personal variation in RNAs in a broad set of cell-types,
we establish pluripotent stem cells from skin. We have IRB approval to
expand our current cohort to 100,000 volunteers.
021: Clinical molecular diagnosis in the era of massively
parallel sequencing: PAP/MAP for monitoring
of therapy or recurrence in breast cancer
Steve Sommer
City of Hope, Duarte, CA, USA
Mortality from breast cancer may be reduced substantially if person-
alized therapy is instituted. Whole exome capture followed by
massively parallel sequencing will soon be available to enumerate all
the cancer-specific protein and microRNA structural changes. With
this information, therapy can be instituted to leverage the enumerated
‘‘weaknesses’’ of the cancer. Once therapy is instituted, monitoring of
therapy or recurrence (MOTOR) can be performed by utilizing the
cancer signature in circulating cells. As a model system to demonstrate
the efficacy of MOTOR, we analyzed plasma to detect breast cancer
mutation signatures of DNA fragments released from apoptotic or
necrotic cancer cells and the DNA of circulating cancer epithelial cells.
Initially, candidate cancer genes were sequenced in breast cancer tissue
samples to identify in each patient a personalized cancer signature of
somatic mutations. Subsequently, pyrophosphorolysis activated poly-
merization (PAP) (http://www.cityofhope.org/PAP), a method for
detecting ultra-rare mutations, was used to detect the cancer-specific
signature in DNA isolated from the plasma and circulating epithelial
cells of patients with non-metastatic breast cancer. Our data demon-
strate the rapid development of PAP assays that routinely detect even a
single copy of the cancer-specific somatic mutations in circulation. The
selectivity of PAP is extremely high, often ranging from at least one
part per million to as high as one part per billion. Circulating levels of
cancer signature mutations and their rates of increase are being mea-
sured at multiple intervals in a multi-year follow up. Our ultimate goal
is to achieve effective monitoring of chemotherapy and to predict
recurrence months to years earlier than currently possible.
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